Search
APL-9
go.drugbank.com/drugs/DB16460InvestigationalIt shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life. … APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation.
Brentuximab
go.drugbank.com/drugs/DB05471InvestigationalIt is available commercially as the monoclonal antibody portion of the antibody-drug conjugate [brentuximab vedotin].
YSIL6
go.drugbank.com/drugs/DB05017ExperimentalThe molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.
Valbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigational[A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. … This approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial.
Thiamine
go.drugbank.com/drugs/DB00152ApprovedInvestigationalNutraceuticalVet approvedThiamine was first discovered by Umetaro Suzuki in Japan when researching how rice bran cured patients of Beriberi.
Butalbital
go.drugbank.com/drugs/DB00241ApprovedIllicitButalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group.
Chlormerodrin
go.drugbank.com/drugs/DB00534ApprovedWithdrawnChlormerodrin is a mercurial compound with toxic side effects that was previously used as a diuretic. The radiolabeled form has been used as a diagnostic and research tool. It is no longer used and has been replaced with new classes of d...
Antihemophilic factor (recombinant), PEGylated
go.drugbank.com/drugs/DB09329ApprovedInvestigationalAntihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label].
Dexamethasone
go.drugbank.com/drugs/DB01234ApprovedInvestigationalVet approvedDexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318]
Omaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigational[A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.